Related Experiment Videos
Excision repair cross complementing-group 1: gene expression and platinum resistance
Ramin Altaha1, Xiaobing Liang, Jing Jie Yu
1Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506-2519, USA. raltaha@hsc.wvu.edu.
International Journal of Molecular Medicine
|November 18, 2004
Summary
High levels of the ERCC1 gene, crucial for DNA repair, are linked to platinum chemotherapy resistance in cancer. Targeting ERCC1 may reverse this resistance, improving patient survival.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Platinum compounds exert cytotoxic effects by forming platinum-DNA adducts.
- Platinum-DNA adduct levels correlate with response to platinum-based chemotherapy.
- Nucleotide excision repair (NER) is implicated in platinum resistance via adduct removal.
Purpose of the Study:
- To review the pathway of ERCC1 gene transcription and translation in cisplatin-exposed cancer cells.
- To summarize the association between ERCC1 levels and platinum resistance.
- To analyze drugs that interfere with ERCC1 expression to reverse platinum resistance.
Main Methods:
- Literature review of studies on cancer cell lines and human cancers.
- Analysis of ERCC1 gene transcription and translation pathways.
- Examination of drug effects on ERCC1 gene expression and platinum resistance.
Main Results:
- High ERCC1 mRNA and/or protein levels are associated with resistance to platinum compounds.
- ERCC1 plays a key role in NER, responsible for platinum-DNA adduct removal.
- Drugs interfering with ERCC1 expression can reverse platinum resistance in cancer cells.
Conclusions:
- ERCC1 expression levels significantly impact platinum resistance and patient survival.
- Targeting ERCC1 offers a potential strategy to overcome platinum resistance in cancer therapy.
- Further research into ERCC1-modulating drugs could enhance platinum-based chemotherapy efficacy.